[{"orgOrder":0,"company":"Medibiofarma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MBF-015","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medibiofarma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medibiofarma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medibiofarma \/ Inapplicable"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Data Management 365 | Atlant Clinical | R-Pharm | UNIMED Laboratories | Exacte Labs | Key Stat | Inpharmus | Ascot E\u011fitim ve Dan\u0131\u015fmanl\u0131k","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"R-Pharm \/ Data Management 365 | Atlant Clinical | R-Pharm | UNIMED Laboratories | Exacte Labs | Key Stat | Inpharmus | Ascot E\u011fitim ve Dan\u0131\u015fmanl\u0131k","highestDevelopmentStatusID":"8","companyTruncated":"R-Pharm \/ Data Management 365 | Atlant Clinical | R-Pharm | UNIMED Laboratories | Exacte Labs | Key Stat | Inpharmus | Ascot E\u011fitim ve Dan\u0131\u015fmanl\u0131k"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Atlant Clinical | UNIMED Laboratories | Data Management 365 | R-Pharm | Inpharmus | Exacte Labs | Key Stat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"R-Pharm \/ Atlant Clinical | UNIMED Laboratories | Data Management 365 | R-Pharm | Inpharmus | Exacte Labs | Key Stat","highestDevelopmentStatusID":"8","companyTruncated":"R-Pharm \/ Atlant Clinical | UNIMED Laboratories | Data Management 365 | R-Pharm | Inpharmus | Exacte Labs | Key Stat"},{"orgOrder":0,"company":"Nobias Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NB-001","moa":"HSV DNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nobias Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nobias Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nobias Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Spruce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Tralesinidase Alfa","moa":"Heparan sulfate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Spruce Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"BioMarin Pharmaceutical \/ Spruce Biosciences"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-083","moa":"Fc fusion protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Stichting European Myeloma Network","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Stichting European Myeloma Network","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Stichting European Myeloma Network \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Stichting European Myeloma Network \/ GSK"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"XOMA","sponsor":"Rezolute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Rezolute","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Rezolute"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Keystone Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Keystone Capital Partners"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Private Placement","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Jefferies"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.29999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ J.P. Morgan"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensoma","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ensoma \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Ensoma \/ Bluebird Bio"},{"orgOrder":0,"company":"Capricor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Cardiosphere-Derived Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Bluebird Bio"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Capricor Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Capricor Therapeutics"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AccurEdit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AccurEdit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Olipudase Alfa","moa":"Sphingomyelin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ RA Capital Management"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ascension Healthcare Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Pegylated Liposome","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascension Healthcare Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ascension Healthcare Development \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascension Healthcare Development \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"I124-AT01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AOC-1001","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Beijing Novikang Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Novikang Medical Technology","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Novikang Medical Technology"},{"orgOrder":0,"company":"Attralus","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AT02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Attralus \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Novotech"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AOC-1044","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Steminent US, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Steminent US, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Steminent US, Inc. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Steminent US, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-CLS-628","moa":"CD3\/CLDN18.2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VX-670","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AccurEdit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AOC-1001","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AOC-1044","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VX-670","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Novotech"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Bluebird Bio"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Public Offering","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ BofA Securities"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ WuXi Biologics"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ RA Capital Management"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KIO-301","moa":"DHODH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"jCyte","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Center for Breakthrough Medicines"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Nanoscope Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Charles River Laboratories, Inc \/ Nanoscope Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Charles River Laboratories, Inc \/ Nanoscope Therapeutics"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Verana Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Verana Health","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Verana Health"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Sepul Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Laboratoires Thea \/ Sepul Bio","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Sepul Bio"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIO-301","moa":"DHODH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"JMKX003142","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Galicaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SOM3355","moa":"Synaptic vesicle amine transporter (SLC18A2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sionna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Galicaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Sionna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Sionna Therapeutics"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABA-A receptor; agonist GABA site","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SOM3355","moa":"Synaptic vesicle amine transporter (SLC18A2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SOM3355","moa":"Synaptic vesicle amine transporter (SLC18A2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Foundation for Prader-Willi Research","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Foundation for Prader-Willi Research","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Foundation for Prader-Willi Research"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Branaplam","moa":"survival motor neurin SMN1 and SMN2 splicing modulators","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Branaplam","moa":"survival motor neurin SMN1 and SMN2 splicing modulators","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Branaplam","moa":"survival motor neurin SMN1 and SMN2 splicing modulators","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ReveraGen BioPharma \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen BioPharma \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"PRG Science & Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Progerinin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PRG Science & Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PRG Science & Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PRG Science & Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ReveraGen BioPharma \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen BioPharma \/ National Institutes of Health"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ReveraGen BioPharma \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen BioPharma \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc | ImagingNMD | SYSNAV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc | ImagingNMD | SYSNAV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc | ImagingNMD | SYSNAV Healthcare"},{"orgOrder":0,"company":"Theravia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravia \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vonafexor","moa":"Bile acid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Theravia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravia \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"Vesalius Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Series C Financing","leadProduct":"Vonafexor","moa":"Bile acid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ Vesalius Biocapital","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ Vesalius Biocapital"},{"orgOrder":0,"company":"Hangzhou Zede Pharma-Tech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CN128","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Hangzhou Zede Pharma-Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hangzhou Zede Pharma-Tech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zede Pharma-Tech \/ Inapplicable"},{"orgOrder":0,"company":"Hangzhou Zede Pharma-Tech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CN128","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Hangzhou Zede Pharma-Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hangzhou Zede Pharma-Tech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zede Pharma-Tech \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ CPRIT"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aradigm","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"Aradigm \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Aradigm \/ Grifols International"},{"orgOrder":0,"company":"Arrevus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Elongation factor G","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrevus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ Inapplicable"},{"orgOrder":0,"company":"Arrevus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Elongation factor G","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrevus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SYNB1618","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SYNB1618","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Morgan Stanley"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral Solution","sponsorNew":"Benuvia Therapeutics \/ Radius Health","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Therapeutics \/ Radius Health"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Public Offering","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Porcine PERT","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cad-1883","moa":"Calcium-activated potassium channel KCa2 (KCNN)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Imara","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardurion Pharmaceutical \/ Imara","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Imara"},{"orgOrder":0,"company":"Jeffrey Zwicker","sponsor":"Quercegen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isoquercitrin","moa":"Aldo-keto reductase family 1 member B1; Angiotensin-converting enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jeffrey Zwicker","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jeffrey Zwicker \/ Quercegen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jeffrey Zwicker \/ Quercegen Pharmaceuticals"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATI-450","moa":"MAPK2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLPG2737","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bocidelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL Vifor \/ Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor \/ Fortrea"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DFV890","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Histamine H3 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Romain Lazor","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Romain Lazor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Romain Lazor \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Romain Lazor \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Amy Tang","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Amy Tang","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amy Tang \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amy Tang \/ Pfizer Inc"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Incyte Corporation"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brensocatib","moa":"Dipeptidyl peptidase I","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Children's Hospital Colorado | Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aardvark Therapeutics \/ Children's Hospital Colorado | Stanford University","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Children's Hospital Colorado | Stanford University"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Pfizer Inc"},{"orgOrder":0,"company":"River 3 Renal Corp.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R3R01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"River 3 Renal Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"River 3 Renal Corp. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"River 3 Renal Corp. \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Basmisanil","moa":"GABA(A) receptor alpha-5 (GABRA5)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Kechow Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Western Sydney Local Health District","sponsor":"Deakin University | Monash University | Royal Perth Hospital | University of Queensland | University of Melbourne","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Western Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Western Sydney Local Health District \/ Deakin University | Monash University | Royal Perth Hospital | University of Queensland | University of Melbourne","highestDevelopmentStatusID":"8","companyTruncated":"Western Sydney Local Health District \/ Deakin University | Monash University | Royal Perth Hospital | University of Queensland | University of Melbourne"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AZ-3102","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nova Mentis Life Science \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"Nova Mentis Life Science \/ KGK Science"},{"orgOrder":0,"company":"Afimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Epeleuton","moa":"Reperfusion stress","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Afimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Afimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/ Inapplicable"},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Neuren Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Neuren Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuren Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inova Health Care Services \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inova Health Care Services \/ Pfizer Inc"},{"orgOrder":0,"company":"Aaron Logan","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aaron Logan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aaron Logan \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Aaron Logan \/ Incyte Corporation"},{"orgOrder":0,"company":"Craig Erickson","sponsor":"Healx","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABA-A receptor; agonist GABA site","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Craig Erickson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Craig Erickson \/ Healx","highestDevelopmentStatusID":"8","companyTruncated":"Craig Erickson \/ Healx"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RLY-2608","moa":"PI3K-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oslo University Hospital \/ Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tebapivat","moa":"PKLR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TPST-1495","moa":"Prostaglandin E2 receptor EP2 (PTGER2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ 5Am Ventures"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Omega Funds"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Eversana","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Maralixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eversana \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eversana \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/ White Lion Capital"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VX-814","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Undisclosed"},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Undisclosed"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"SLC40A1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olinciguat","moa":"Soluble guanylate cyclase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calcilytix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Encaleret","moa":"calcium receptor antagonists","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calcilytix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calcilytix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calcilytix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"30 Technology","sponsor":"ConvaTec","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"RESP301","moa":"Membrane fusion protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"30 Technology","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"30 Technology \/ ConvaTec","highestDevelopmentStatusID":"8","companyTruncated":"30 Technology \/ ConvaTec"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Deutivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL1211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"SRW Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NEW ZEALAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fisetin","moa":"Cyclin-dependent kinase 6; Fatty acid synthase; Cyclin homolog","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SRW Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SRW Laboratories \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SRW Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Public Offering","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jupiter Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Jupiter Neurosciences \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Jupiter Neurosciences \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":2.8999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.8999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Shionogi","sponsor":"Jordan\u2019s Guardian Angels","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shionogi \/ Jordan\u2019s Guardian Angels","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Jordan\u2019s Guardian Angels"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Tisento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Tisento Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Tisento Therapeutics"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Invus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Invus","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Invus"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Organovo Holdings"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NADPH oxidase 4 | NADPH oxidase 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Cyan Bio","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Elocalcitol","moa":"Vitamin D receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyan Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyan Bio \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cyan Bio \/ Adge Pharmaceuticals"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GLPG2737","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ University of California"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sanford Burnham Prebys","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"N-Acetyl-D-Leucine","moa":"Alkaline phosphatase, tissue-nonspecific isozyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Sanford Burnham Prebys","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Sanford Burnham Prebys"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Rege Nephro","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Acquisition","leadProduct":"Tamibarotene","moa":"Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syros Pharmaceuticals \/ Rege Nephro","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Rege Nephro"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TPST-1495","moa":"Prostaglandin E2 receptor EP2 (PTGER2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VX-864","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RGH-706","moa":"TAAR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"PXE International","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DS-1211b","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ PXE International","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ PXE International"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VX-864","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Portal Therapeutics","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PORT-77","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Portal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portal Therapeutics \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Portal Therapeutics \/ Celerion"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NADPH oxidase 4 | NADPH oxidase 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Zhejiang Hangyu Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JMKX003142","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Zhejiang Hangyu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Zhejiang Hangyu Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Panakes Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Panakes Partners","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Panakes Partners"},{"orgOrder":0,"company":"PRG Science & Technology Co., Ltd.","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Progerinin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PRG Science & Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PRG Science & Technology Co., Ltd. \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"PRG Science & Technology Co., Ltd. \/ Amarex Clinical Research"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Muscular Dystrophy Association","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Muscular Dystrophy Association","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Muscular Dystrophy Association"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Bloom Burton Securities","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/ White Lion Capital"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Vonafexor","moa":"Bile acid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NADPH oxidase 4 | NADPH oxidase 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NADPH oxidase 4 | NADPH oxidase 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Branaplam","moa":"survival motor neurin SMN1 and SMN2 splicing modulators","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ RA Capital Management"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Clinigen Group","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Clinigen Group"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Charite University, Berlin, Germany \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"University of Washington","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"University of Washington \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ Genentech"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ALXN1820","moa":"Complement factor P (CFP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ypsomed \/ Astria Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Ypsomed \/ Astria Therapeutics"},{"orgOrder":0,"company":"Filip Krag Knop","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Filip Krag Knop","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Filip Krag Knop \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Filip Krag Knop \/ Zealand Pharma"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Percheron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ATL1102","moa":"ITGA4 messenger RNA (ITGA4 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Percheron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Percheron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Percheron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ATL1102","moa":"ITGA4 messenger RNA (ITGA4 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ATL1102","moa":"ITGA4 messenger RNA (ITGA4 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ATL1102","moa":"ITGA4 messenger RNA (ITGA4 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"microRNA 21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Lademirsen","moa":"microRNA 21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"microRNA 21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"The Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ The Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ The Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Zikani Therapeutics","sponsor":"Eloxx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zikani Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zikani Therapeutics \/ Eloxx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Zikani Therapeutics \/ Eloxx Pharmaceuticals"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DS-5141b","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"The National Research Council of Canada Industrial Research Assistance Program","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Qbkpn SSI","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ The National Research Council of Canada Industrial Research Assistance Program","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ The National Research Council of Canada Industrial Research Assistance Program"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"National Research Council of Canada Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"QBKPN SSI","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ IQVIA"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Zafgen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Zafgen","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Zafgen"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"REC-994","moa":"Superoxide Radical","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unity Health Toronto \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ US Department of Defense"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"National Institutes of Health | University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unity Health Toronto \/ National Institutes of Health | University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ National Institutes of Health | University of California, San Francisco"},{"orgOrder":0,"company":"Aceragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Elongation factor G","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aceragen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aceragen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Intergroupe Francophone du Myelome","sponsor":"Sanofi | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Intergroupe Francophone du Myelome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intergroupe Francophone du Myelome \/ Sanofi | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Intergroupe Francophone du Myelome \/ Sanofi | Bristol Myers Squibb"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Children's National Research Institute","sponsor":"Alberta Children's Hospital | The Hospital for Sick Children | Levine Children's Hospital | Ann & Robert H Lurie Children's Hospital of Chicago | Nationwide Children\u2019s Hospital | Children's Hospital at Montefiore | Doris Duke Foundation | Johnson & Johnso","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Children's National Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's National Research Institute \/ Alberta Children's Hospital | The Hospital for Sick Children | Levine Children's Hospital | Ann & Robert H Lurie Children's Hospital of Chicago | Nationwide Children\u2019s Hospital | Children's Hospital at Montefiore | Doris Duke Foundation | Johnson & Johnso","highestDevelopmentStatusID":"8","companyTruncated":"Children's National Research Institute \/ Alberta Children's Hospital | The Hospital for Sick Children | Levine Children's Hospital | Ann & Robert H Lurie Children's Hospital of Chicago | Nationwide Children\u2019s Hospital | Children's Hospital at Montefiore | Doris Duke Foundation | Johnson & Johnso"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Capricor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AGTC-501","moa":"X-linked retinitis pigmentosa GTPase regulator (RPGR)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"SAR422459","moa":"ABCR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biomedica \/ Sanofi"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Children's Healthcare of Atlanta | Children's Hospital Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Polyinosinic Acid","moa":"Immune","graph1":"Genetic Disease","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Children's Healthcare of Atlanta | Children's Hospital Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ Children's Healthcare of Atlanta | Children's Hospital Los Angeles"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"NS-089","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nippon Shinyaku \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nippon Shinyaku \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"NS-089","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"BW-20805","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NFlection Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NFX-179","moa":"ERK activator kinase (MEK)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NFlection Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"NFlection Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFlection Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stargazer Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"STG-001","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Stargazer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stargazer Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stargazer Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Heart, Lung, and Blood Institute","sponsor":"Quercis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isoquercitrin","moa":"Aldo-keto reductase family 1 member B1; Angiotensin-converting enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"National Heart, Lung, and Blood Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Heart, Lung, and Blood Institute \/ Quercis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"National Heart, Lung, and Blood Institute \/ Quercis Pharma"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ML Bio Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BBP-418","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ML Bio Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"ML Bio Solutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ML Bio Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sulindac","moa":"Cyclooxygenase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tufts Medical Center \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Tufts Medical Center \/ Sanofi"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Elizabeth Berry-Kravis","sponsor":"FRAXA Research Foundation | Purposeful IKE","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroergotoxine Mesylate","moa":"Monoamine oxidase (MAO)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Elizabeth Berry-Kravis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elizabeth Berry-Kravis \/ FRAXA Research Foundation | Purposeful IKE","highestDevelopmentStatusID":"8","companyTruncated":"Elizabeth Berry-Kravis \/ FRAXA Research Foundation | Purposeful IKE"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Probenecid","moa":"Solute carrier family 22 member 6 | Solute carrier family 22 member 8 | Solute carrier family 22 member 11","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Otsuka Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Otsuka Holdings"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PTC518","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ELX-02","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zomagen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VTX2735","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zomagen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zomagen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zomagen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI1291583","moa":"DPP-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jerry Vockley","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Triheptanoin","moa":"Triglyceride","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jerry Vockley","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jerry Vockley \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Jerry Vockley \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Jerry Vockley","sponsor":"Acer Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jerry Vockley","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jerry Vockley \/ Acer Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jerry Vockley \/ Acer Therapeutics"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Film","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PTC518","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rege Nephro Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spinogenix \/ Avance Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Avance Clinical"},{"orgOrder":0,"company":"Italfarmaco","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Italfarmaco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italfarmaco \/ Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"Italfarmaco \/ Fortrea"},{"orgOrder":0,"company":"Jerry Vockley","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jerry Vockley","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jerry Vockley \/ Zevra Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jerry Vockley \/ Zevra Therapeutics"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Desidustat","moa":"enzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Indian Council of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"AUG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ AUG Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ AUG Therapeutics"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NFlection Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NFX-179","moa":"ERK activator kinase (MEK)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NFlection Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"NFlection Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFlection Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CDG Care","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CDG Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDG Care \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"CDG Care \/ Cerecor"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"DCI Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Series B Financing","leadProduct":"Tamibarotene","moa":"Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ DCI Partners","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ DCI Partners"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ Inapplicable"},{"orgOrder":0,"company":"Stargazer Pharmaceuticals","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"STG-001","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Stargazer Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Stargazer Pharmaceuticals \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Stargazer Pharmaceuticals \/ Organovo Holdings"},{"orgOrder":0,"company":"Solaxa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fampridine","moa":"Voltage-gated potassium channel","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Solaxa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Solaxa \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Solaxa \/ Inapplicable"},{"orgOrder":0,"company":"Tracey McLaughlin","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tracey McLaughlin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tracey McLaughlin \/ Eiger BioPharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Tracey McLaughlin \/ Eiger BioPharmaceuticals"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Talfirastide","moa":"AGTR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Constant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"peptides","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recifercept","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recifercept","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CTI-1601","moa":"Soluble guanylate cyclase (GCS)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ApcinteX","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SerpinPC","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ApcinteX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ApcinteX \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ApcinteX \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CTI-1601","moa":"Soluble guanylate cyclase (GCS)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"ReNeuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReNeuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ReNeuron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReNeuron \/ Inapplicable"},{"orgOrder":0,"company":"AzurRx SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MS1819-SD","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AzurRx SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AzurRx SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AzurRx SAS \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HM15136","moa":"GLP-1R\/GIPR\/GCGR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Metro International Biotech","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MIB-626","moa":"NAD+","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Metro International Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Metro International Biotech \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"8","companyTruncated":"Metro International Biotech \/ Children's Hospital of Philadelphia"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akershus University Hospital \/ The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MBM-01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matrix Biomed \/ University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Matrix Biomed \/ University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"David Williams","sponsor":"National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM) | Bluebird Bio | Blood and Marrow Transplant Clinical Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous CD34+ Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"David Williams","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"David Williams \/ National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM) | Bluebird Bio | Blood and Marrow Transplant Clinical Trials Network","highestDevelopmentStatusID":"8","companyTruncated":"David Williams \/ National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM) | Bluebird Bio | Blood and Marrow Transplant Clinical Trials Network"},{"orgOrder":0,"company":"Columbia University","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"124-I Evuzamitide","moa":"MUC1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Attralus","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Attralus"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAR447537","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAR447537","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Thiogenesis Therapeutics, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TTI-0102","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Thiogenesis Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thiogenesis Therapeutics, Inc. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Thiogenesis Therapeutics, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"REC-994","moa":"Superoxide Radical","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Recursion Pharma","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"Recursion Pharma \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Recursion Pharma \/ Bayer AG"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"R42 Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Healx \/ R42 Group","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ R42 Group"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat | Metrum Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CTI-1601","moa":"Soluble guanylate cyclase (GCS)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larimar Therapeutics \/ Veristat | Metrum Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat | Metrum Research Group"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"}]
Find Drugs for Genetic Disease in Phase II Clinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target